Media headlines about Edwards Lifesciences (NYSE:EW) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Edwards Lifesciences earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 46.9470635606436 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:

Several analysts recently commented on EW shares. SunTrust Banks set a $124.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Canaccord Genuity reiterated a “buy” rating and set a $135.00 target price (down from $155.00) on shares of Edwards Lifesciences in a research report on Wednesday, October 25th. Cowen reiterated a “buy” rating and set a $135.00 target price on shares of Edwards Lifesciences in a research report on Thursday, October 12th. BMO Capital Markets restated a “buy” rating and issued a $137.00 price objective on shares of Edwards Lifesciences in a research report on Friday, December 8th. Finally, Barclays lowered their price objective on Edwards Lifesciences from $120.00 to $118.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 25th. Six research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Edwards Lifesciences presently has a consensus rating of “Buy” and an average price target of $129.57.

Edwards Lifesciences (EW) opened at $128.04 on Monday. The company has a market capitalization of $27,121.21, a P/E ratio of 37.26, a PEG ratio of 2.05 and a beta of 0.51. Edwards Lifesciences has a 52 week low of $86.55 and a 52 week high of $128.61. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.76 and a current ratio of 3.49.

Edwards Lifesciences declared that its board has approved a share repurchase plan on Thursday, December 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company’s board believes its stock is undervalued.

In other Edwards Lifesciences news, VP Larry L. Wood sold 6,300 shares of the company’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $121.00, for a total transaction of $762,300.00. Following the completion of the sale, the vice president now owns 116,148 shares in the company, valued at $14,053,908. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Michael A. Mussallem sold 32,800 shares of the company’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $114.97, for a total value of $3,771,016.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 159,620 shares of company stock worth $17,904,375. Insiders own 2.13% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was originally reported by Marea Informative and is the property of of Marea Informative. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.mareainformativa.com/2018/01/29/edwards-lifesciences-ew-given-media-impact-score-of-0-19-updated-updated-updated.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.